CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients

The chimera antigen receptor (CAR) T cell therapy is a novel and potential targeted therapy and has achieved satisfactory efficacy in patients with relapsed or refractory multiple myeloma (MM) in recent years. However, cytokine release syndrome (CRS) and clinical efficacy have become the major obsta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ke, Mengying, Kang, Liqing, Wang, Ling, Yang, Shu, Wang, Yajun, Liu, Haiyan, Gu, Chunyan, Huang, Hongming, Yang, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191024/
https://www.ncbi.nlm.nih.gov/pubmed/34108020
http://dx.doi.org/10.1186/s13045-021-01101-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191024/
https://www.ncbi.nlm.nih.gov/pubmed/34108020
http://dx.doi.org/10.1186/s13045-021-01101-6

Ejemplares similares